EMA Reduces Trial Requirements For Hemophilia Drugs
New guidance from the EMA says that data from patient disease registries can be used instead of clinical trials of previously untreated patients during the development of new treatments for hemophilia.
You may also be interested in...
The European Medicines Agency chief Guido Rasi is worried that if work on guidance development and revision stutters, "the whole system may suffer."
As Europe’s health emergency body HERA approaches its first anniversary, an unprecedented range of stakeholders including industry bodies will be meeting in December to discuss HERA’s achievements, while a separate event will showcase the next generation of vaccines for COVID-19 and other infections.
The European health commissioner has told members of parliament that a balance needs to be struck between promoting innovation and maximizing access to medicines across the EU member states.